What Happened?
Cambridge, MA-based Casebia Appointed Stephen Kennedy as Senior Vice President and Head of Technical Operations
About the Company
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
About the Person
Stephen Kennedy is Senior Vice President and Head of Technical Operations at Casebia. Previously, Stephen held various senior IT leadership roles in the industry.
Info Source
News
Short Profile